AXGN
AxoGen Inc is a medical technology company dedicated to peripheral nerve repair. It provide products and education to improve surgical treatment algorithms for peripheral nerve injuries.
Axogen, Inc. (AXGN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Value (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C- (2.1) | B (3.3) | B (3.3) | C+ (2.7) | C+ (2.6) | C+ (2.8) |
| 2026-11-10 | C (2.2) | B (3.4) | B (3.3) | C+ (2.7) | C+ (2.6) | B- (2.9) |
| 2026-11-03 | C (2.3) | B (3.3) | B (3.3) | C+ (2.8) | C+ (2.7) | B- (2.9) |
| 2026-10-27 | C+ (2.5) | B- (3.0) | B (3.3) | B- (2.9) | C+ (2.6) | B- (2.9) |
| 2026-10-20 | C+ (2.6) | B- (3.0) | B (3.3) | B- (3.0) | C+ (2.6) | B- (2.9) |